Professional Documents
Culture Documents
Departement of Internal Medicine Airlangga School of Medicine-dr.Soetomo Teaching Hospital Surabaya 2009
INTRODUCTION
Immunohistochemically KIT +, mesenchymal neoplasm of the GI tract and abdomen Locations: stomach ( 50%-70%), small bowel (20%- 40%) and <5% in the rectum, esofagus, omentum and mesenterium
GIST
CASE
Chief complaint :
Vomitus
of coffee ground
material Black stool Early satiety, nausea, abdominal discomfort Decreased appetite Fatigue, pale
Physical Examination
Alert, weak, GCS 456, BP 110/70 mmHg, pulse 92 x/m, RR 20x/m, axillary temp. 36.8C Anemia (+) Heart & Lung : no abnormality, spider nevi - /H/L: unpalpable, mass in epigastrium to left hypocondrium region 8x8 cm, fixed, not well defined
Laboratory studies
Hb 5.1 g/dl WBC 9,800/mm3 Plt 820,000/mm3 LED 20/60 Coagulation test no abnormality Urinalysis no abnormality Blood sugar 128 mg/dl Creatinine serum 0.7 mg/dl BUN 10 mg/dl
AST 62 IU/L ALT 35 IU/L total protein 4.8 g/dL albumin 2.42 g/dL globulin 2.4 g/dL potassium 3.47 mmol/L sodium 132 mmol/L chlorida 99.3 mmol/L
Imaging studies
Abdominal USG : mass 4x 10 cm trace from gaster, liver was normal ( no nodul/ cyst/abses)
Upper endoscopy
1st Endoscopy (Sept,17, 2008): tumor at the corpus that covered posterior wall, minor and major curvatura. Conclusion suspect gaster carcinoma. 1st Biopsy : erosive gastritis
2nd Endoscopy (Nov,3, 2008): no erosion and esophagus varices. Conclusion : mass in the corpus gaster that caused obstruction (suspected as malignancy) 2nd biopsy : chronic gastritis
Imaging studies
Solid mass in the gaster wall 12.2 x 9.4 cm , unclear border, inhomogen contrast enhancement. No liver enlargement. No nodul/mass/cyst. Spleen/ Pancreas/Ren D/S were normal. No bone destruction. Conclusion : mass in the gaster wall.
FNAB,CT Scan guiding (Nov, 27, 2008) : hypercellular consist of group and spreading of spindle cell nucleus partly plump and lobulated, pleiomorfik , coarse chromatin, and matrix myxoid. Conclusion spindle mesenchymal tumor
Planning Dx :
Planning Tx :
Imaging studies
Upper GI X-Ray( Des, 5, 2008) : ground glass appearance at the upper left , minimal gas in the gaster. Filling defect with fungating type and ulcerative type, destroyed mucosal pattern in the corpus until anthrum gaster
Progress Note
No hematemesis melena. Consultation to digestive surgery : Gastric malignancy and Dec, 2, post HM. Planning Dx. Upper GI X-Ray , CEA, 2008 Ca19-9 Dec, 5, 2008
Upper GI : filling defect , fungating & ulcerative type, destroyed mucosal pattern in the corpus until anthrum gaster . CEA 0.8 ng/ml ( < 5 ) ; Ca 19-9 1.2 U/ml ( < 37)
The patient underwent operation. Tumor was unresectable because the tumor adhered at the porta vein and multiple Dec,22, nodul in liver. Jejunostomy was done for enteral feeding 2008 No complaint The patient discharged from the hospital and refused to be treated with chemotheraphy Jan,16, 2009 Advice : controlled to gastrohepatology ,hematologyoncology & surgery clinic
Hystopatology
Imunohistochemistry
Malignant tissue tumor: anaplastic cell proliferation, pleiomorphic round nucleus, hyperchromatic, mitosis >20/10 HPF, trabecular formed, Conclusion: high grade malignancy dd. adenocarcinoma poorly differentiated ; stromal tumor.
DISCUSSION
non-specific : early satiety, bloating, non specific abdominal pain, gastrointestinal bleeding , fatigue from anemia, or obstruction. Abdominal pain, melena and weight loss most common symptoms Rarely, an abdominal mass is palpable
This patient : hematemesis-melena, weight loss, anemia, palpable mass in the abdomen
Laboratory examination
This patient : anemia and hypoalbumin. The tumor markers (CEA and Ca 19-9) were negative
Imaging studies
no standard imaging protocol, all imaging techniques may be used. preoperative diagnosis based on clinical and radiologic data is difficult nonspecific presentation typically grow as bulky, well-defined, endo- or exophytic masses parallel to the bowel lumen stromal origin normally present with the typical signs of submucosal or extrinsic GI lesions on imaging studies overlying mucosa can be normal or show signs of necrosis or ulceration.
Imaging studies
Endoscopic examination :smooth protrusion of the bowel wall, lined with mucosa, some cases show signs of bleeding and ulceration Full layer biopsy true histopathologic Dx. GIST: 27-50% by endoscopic biopsy The results : gastric tumor and the biopsy revealed erosive and chronic gastritis
Barium series detect GIST sufficient size filling defect : sharply demarcated and is elevated compared with surrounding mucosa overlying mucosa is smooth unless ulceration the information is limited because of striking image Upper GI : mass in the corpus to anthrum gaster , fungating & ulcerative type with destroyed mucosal pattern
Imaging studies
USG studies : well-defined or polylobulated solid masses. Cystic changes,necrosis, or calcifications. image quality is often degraded by intervening bowel gas USG studies : mass 4x10 cm and no abnormality in the other structures
CT Scan : important in the diagnosis and staging of GIST Detect multiple tumors and provide evidence of metastatic spread less aggressive GIST : < 5 cm, well-defined, round or oval, exophytic masses and homogeneous enhancement Aggressive GIST : irregular and lobulated margins, >10 cm, central necrosis, ulceration, and heterogeneous contrast enhancement CT Scan : solid mass 12.2 x 9.4 cm in the gastric wall , irregular, heterogenous contrast enhancement , no metastatic to adjacent organs.
Biopsy
GIST tend to fall into three categories of morphology epitheloid, spindle cell, or mixed The diagnosis of GIST relies on histopatology and imunohistochemistry CD 117 is generally positive
FNAB with CT scan guiding: spindle mesenchymal tumor Biopsy durante op : adenocarcinoma dd. Stromal tumor Imunohistochemistry: CD 117 positive
Kim, 2005
Therapy
Surgical : definitive therapy 1. Complete resection : recurrent < 2. Incomplete resection : locally advanced or metastatic disease Medical : 1. conventional radiotherapy and chemotherapy are ineffective 2. Imatinib mesylate is recommended as adjuvant therapy
This patient underwent operation : tumor was unresectable, planning for receive Imatinib mesylate but the patient refused
Prognosis
1-YSR metastatic disease: 70% 2-YSR metastatic disease : 47% 5-YSR Post Resection : 30-65% Median Survival Time with Imatinib: > 36 months Recurrence Rate 40-52%
This patient was classified in to high risk GIST, metastatic disease and unresectable tumor. The prognosis was poor.
Summary
We have reported a patient with Gastrointestinal stromal tumor with liver metastases The diagnosis of GIST based on histopathology and imunohistochemistry examination The patient underwent operation but the tumor was unresectable. Jejunostomy was done for enteral feeding The patient was classified in to high risk GIST the prognosis was poor
THANK YOU
Kim,2005
Kim,2005
Rubin,2007
Rubin,2007
Rubin,2007
Rubin,2007
Rubin,2007
Rubin,2007
Rubin,2007
Rubin,2007
Rubin,2007
Rubin,2007
Miettinen,2006
Miettinen, 2006
Immunohistochemical differential diagnosis of the most important mesenchymal tumor of the GI tract
Miettinen, 2003
Miettinen, 2003
Demetri, 2004
Demetri, 2004